The Effectiveness of HPV Vaccination on the Incidence of Oropharyngeal Cancers in Men: a Review

Overview

Journal Infect Agent Cancer

Publisher Biomed Central

Specialty Infectious Diseases

Date 2023 Apr 24

PMID 37095546

Authors

Philip Macilwraith

Eve Malsem

Sathana Dushyanthen

Affiliations

Soon will be listed here.

Abstract

Background: Human Papilloma Virus (HPV) contributes to the development of oropharyngeal cancer (OPC) and is currently the leading cause of OPC in the Western world. There have been limited studies examining the effect of HPV-vaccination on OPC incidence in men. This review aims to interrogate relationship linking HPV-vaccination and OPC in men, to potentially recommend pangender HPV-vaccination, to reduce the incidence of HPV associated OPC.

Main Body: A review was carried out using Ovid Medline, Scopus and Embase databases, on 22nd October 2021 investigating the effect of HPV-vaccination on OPC prevalence in men and including studies with vaccination data pertaining to men in the past 5 years, while excluding those studies without appropriate oral HPV-positivity data and non-systematic reviews. Studies were evaluated as per the PRISMA guidelines and ranked using risk of bias tools including RoB-2, ROBINS-1 and the NIH quality assessment tools. 7 studies were included ranging from original research to systematic review articles. All studies were published in English from 2017 to 2021. Overall, these suggested that HPV-vaccination reduced levels of oral HPV positivity in men. This was thought to be indicative of a reduced risk of development of HPV-associated OPC. A limitation of this study was the inability to conduct meta-analysis due to the heterogeneity of included studies. We noted a significant impact on the reduction of HPV positivity post HPV-vaccination and a potential contribution to reducing the future incidence of OPC.

Conclusion: This review makes a strong case for pangender HPV-vaccination in combatting OPC in men.

Citing Articles

Co-infection of human papillomavirus genotypes and Epstein-Barr virus in tumors of the oral cavity and oropharynx: a retrospective study in Northeastern Mexico.

Palacios-Saucedo G, Vazquez-Guillen J, Alanis-Valdez A, Valdez-Trevino L, Galindo-Mendez L, Zavala-Pompa A IJID Reg. 2025; 14:100555.

PMID: 39877418 PMC: 11772935. DOI: 10.1016/j.ijregi.2024.100555.

Oral and periodontal manifestation related during human papilloma virus infections: Update on early prognostic factors.

Amato M, Santonocito S, Bruno M, Polizzi A, Mastroianni A, Chaurasia A Heliyon. 2024; 10(10):e31061.

PMID: 38813162 PMC: 11133762. DOI: 10.1016/j.heliyon.2024.e31061.

Assessing the Knowledge of HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Vaccination, and Practice Scope among Saudi Dental Students in the Western Region.

Alsharif M, Alsahafi E Healthcare (Basel). 2024; 12(9).

PMID: 38727462 PMC: 11083101. DOI: 10.3390/healthcare12090905.

References

Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G . Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?. Int J Cancer. 2009; 125(2):362-6. DOI: 10.1002/ijc.24339. View

Hong A, Lee C, Jones D, Veillard A, Zhang M, Zhang X . Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades. Head Neck. 2014; 38(5):743-50. DOI: 10.1002/hed.23942. View

Guo T, Eisele D, Fakhry C . The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer. 2016; 122(15):2313-23. PMC: 4956510. DOI: 10.1002/cncr.29992. View

Bersani C, Mints M, Tertipis N, Haeggblom L, Sivars L, Ahrlund-Richter A . A model using concomitant markers for predicting outcome in human papillomavirus positive oropharyngeal cancer. Oral Oncol. 2017; 68:53-59. DOI: 10.1016/j.oraloncology.2017.03.007. View

Nielsen K, Jakobsen K, Jensen J, Gronhoj C, von Buchwald C . The Effect of Prophylactic HPV Vaccines on Oral and Oropharyngeal HPV Infection-A Systematic Review. Viruses. 2021; 13(7). PMC: 8310210. DOI: 10.3390/v13071339. View

Jamieson L, Garvey G, Hedges J, Leane C, Hill I, Brown A . Cohort profile: indigenous human papillomavirus and oropharyngeal squamous cell carcinoma study - a prospective longitudinal cohort. BMJ Open. 2021; 11(6):e046928. PMC: 8183277. DOI: 10.1136/bmjopen-2020-046928. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021; 88:105906. DOI: 10.1016/j.ijsu.2021.105906. View

Daniel C, Atkins A . HPV vaccination disparities and strategies to prevent oropharyngeal cancer in males. Prev Med Rep. 2021; 24:101521. PMC: 8383099. DOI: 10.1016/j.pmedr.2021.101521. View

Wilkin T, Chen H, Cespedes M, Leon-Cruz J, Godfrey C, Chiao E . A Randomized, Placebo-Controlled Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Adults Aged 27 Years or Older: AIDS Clinical Trials Group Protocol A5298. Clin Infect Dis. 2018; 67(9):1339-1346. PMC: 6186857. DOI: 10.1093/cid/ciy274. View

10.

Chaturvedi A, Graubard B, Broutian T, Pickard R, Tong Z, Xiao W . Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol. 2017; 36(3):262-267. PMC: 5773841. DOI: 10.1200/JCO.2017.75.0141. View

11.

Morais E, El Mouaddin N, Schuurman S, De A . Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data. Vaccine. 2021; 39(39):5461-5473. DOI: 10.1016/j.vaccine.2021.08.043. View

12.

Katz J . The impact of HPV vaccination on the prevalence of oropharyngeal cancer (OPC) in a hospital-based population: A cross-sectional study of patient's registry. J Oral Pathol Med. 2020; 50(1):47-51. DOI: 10.1111/jop.13091. View

13.

Fakhry C, Rosenthal B, Clark D, Gillison M . Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila). 2011; 4(9):1378-84. PMC: 3380432. DOI: 10.1158/1940-6207.CAPR-11-0284. View

14.

Takes R, Wierzbicka M, DSouza G, Jackowska J, Silver C, Rodrigo J . HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?. Oral Oncol. 2015; 51(12):1057-60. DOI: 10.1016/j.oraloncology.2015.10.011. View

15.

McGuinness L, Higgins J . Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2020; 12(1):55-61. DOI: 10.1002/jrsm.1411. View

16.

Bogaards J, Wallinga J, Brakenhoff R, Meijer C, Berkhof J . Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015; 350:h2016. PMC: 4428278. DOI: 10.1136/bmj.h2016. View

17.

Timbang M, Sim M, Bewley A, Farwell D, Mantravadi A, Moore M . HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother. 2019; 15(7-8):1920-1928. PMC: 6746516. DOI: 10.1080/21645515.2019.1600985. View

18.

Agalliu I, Gapstur S, Chen Z, Wang T, Anderson R, Teras L . Associations of Oral α-, β-, and γ-Human Papillomavirus Types With Risk of Incident Head and Neck Cancer. JAMA Oncol. 2016; 2(5):599-606. PMC: 4956584. DOI: 10.1001/jamaoncol.2015.5504. View

19.

MacCosham A, El-Zein M, Burchell A, Tellier P, Coutlee F, Franco E . Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: a randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couples. BMJ Open. 2020; 10(8):e039383. PMC: 7422656. DOI: 10.1136/bmjopen-2020-039383. View

20.

Parker K, Kemp T, Isaacs-Soriano K, Abrahamsen M, Pan Y, Lazcano-Ponce E . HPV-specific antibodies at the oral cavity up to 30 months after the start of vaccination with the quadrivalent HPV vaccine among mid-adult aged men. Vaccine. 2019; 37(21):2864-2869. PMC: 9732814. DOI: 10.1016/j.vaccine.2019.03.064. View